Incannex Healthcare Inc. reported a comprehensive loss of USD 6.81 million for the second quarter (Q2) ended December 31, 2025. For the half year $(HY)$ ended December 31, 2025, the comprehensive loss totaled USD 12.99 million, representing a 14 percent increase. The company did not generate revenue from customers for the three and six months ended December 31, 2025, and indicated it does not expect to generate material revenue until its drug candidates are approved. Research and development expenses remained a primary cost driver, reflecting ongoing clinical and preclinical development activities, including external costs related to contract research organizations, contract manufacturers, consultants, and other third-party partners supporting clinical trials and preclinical studies. During the period, Incannex Healthcare Inc. increased its share of earnings from its joint venture investment in Mind Clinics Australia by USD 17,000 for the half year. The company also noted a currency translation adjustment, net of tax, which increased by USD 0.1 million for the half year due to the appreciation of the Australian dollar against the U.S. dollar. Key product updates include continued clinical development of lead drug candidates: IHL-42X for the treatment of obstructive sleep apnea (OSA), PSX-001 (a psilocybin treatment in combination with psychological therapy for patients with generalized anxiety disorder), and IHL-675A. These candidates are currently in Phase 2/3 and Phase 2 clinical development stages.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-015867), on February 13, 2026, and is solely responsible for the information contained therein.